1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. Company
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo WuXi Biologics (Cayman) Inc.
WUXI BIOLOGICS (CAYMAN) INC. is an investment holding company. The Company along with its subsidiaries is mainly engaged in the discovery, research and development, manufacturing and sales of biologics products. The Company’s primary products include the clinical active pharmaceutical ingredients, sterile liquid preparations, freeze-dried preparations, as well as small molecules antibiotics for injection drugs. The Company mainly distributes its products in the United States of America (USA) and the People’s Republic of China (PRC) markets.

Number of employees : 9 864 people.
Sales per Business
20202021Delta
Research Services on Fee-for-Service6 022.8095.5%9 684.2878.1% +60.79%
Commercial Manufacturing Contracts37.670.6%1 987.7416% +5176.62%
Other Biologics Products95.781.5%418.123.4% +336.54%
Research Services on Full-Time-Equivalent148.052.3%289.872.3% +95.8%
Project Management Organization Services2.30-21.660.2% +839.98%
HKD in Million
Sales per region
20202021Delta
North America2 785.8144.2%6 301.8950.8% +126.21%
China2 768.9143.9%3 025.9724.4% +9.28%
Europe501.858%2 743.3822.1% +446.66%
Rest of the World250.034%330.452.7% +32.16%
HKD in Million
Managers
Name Title Age Since
Zhi Sheng Chen Director 48 2014
Ming Tu Chief Financial Officer & Executive Vice President 53 2021
Weichang Zhou Chief Technology Officer & Executive Director 58 2016
Pik Yuk Cheng Joint Secretary 63 2017
Yue Huang Co-Secretary - 2018
Chiang Syin, Dr. Chief Quality Officer 67 2018
Zhi Ling Ji Head-Legal - -
Members of the board
Name Title Age Since
Ge Li, Dr. Non-Executive Chairman 55 2014
William Robert Keller Independent Non-Executive Director 73 2017
Teh Ming Kwauk Independent Non-Executive Director 68 2017
Kenneth Walton Hitchner Independent Non-Executive Director 60 2020
Zhi Sheng Chen Director 48 2014
Ning Zhao, Dr. Non-Executive Director 55 2021
Weichang Zhou Chief Technology Officer & Executive Director 58 2016
Yan Ling Cao Non-Executive Director 37 2016
Yi Bing Wu, Dr. Non-Executive Director 53 2016
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 4,218,527,082 3,553,755,045 84.2% 0 0.0% 84.2%
Shareholders
NameEquities%
Wuxi Biologics Holdings Ltd. 650,251,133 15.4%
Capital Research & Management Co. (World Investors) 287,262,037 6.81%
The Vanguard Group, Inc. 102,861,059 2.44%
BlackRock Fund Advisors 96,513,500 2.29%
JPMorgan Investment Management, Inc. 96,257,000 2.28%
Invesco Advisers, Inc. 79,976,020 1.90%
Capital Research & Management Co. (Global Investors) 69,291,216 1.64%
JPMorgan Asset Management (Asia Pacific) Ltd. 60,403,000 1.43%
WCM Investment Management LLC 52,269,047 1.24%
Fidelity Management & Research Co. LLC 49,563,214 1.18%
Holdings
NameEquities%Valuation
MORIMATSU INTERNATIONAL HOLDINGS COMPANY LIMITED (2155) 18,856,000 1.82% 17,807,795 USD
I-MAB 1,156,110 0.65% 6,302,117 USD
Company contact information
Wuxi Biologics (Cayman), Inc.
No. 108, Meiliang Road
Mashan
Wuxi, Jiangsu 214092

Phone : +86.510.81831205
Web : http://www.wuxibiologics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of WuXi Biologics (Cayman) Inc.